A Single Arm, Open Label, Phase 1b Study of Xevinapant in Combination With Weekly Cisplatin and Intensity-modulated Radiotherapy to Assess Safety and Tolerability in Participants With LA SCCHN, Suitable for Definitive Chemoradiotherapy (HyperlynX)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 20 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Xevinapant (Primary) ; Cisplatin
Indications Carcinoma; Head and neck cancer; Squamous cell cancer
Focus Adverse reactions
Acronyms HyperlynX
Sponsors EMD Serono Research & Development Institute

Most Recent Events

16 Sep 2024 Status changed from active, no longer recruiting to discontinued. (No major safety concerns were identified in HyperlynX study, but Lack of evidence of efficacy of meaningful clinical benefit.)
18 Jul 2024 Planned End Date changed from 16 Apr 2025 to 30 Aug 2024.
18 Jul 2024 Planned primary completion date changed from 1 Apr 2025 to 30 Aug 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight